NVision Quantum Technologies GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NVision Quantum Technologies GmbH - overview
Established
2015
Location
Ulm, -, Germany
Primary Industry
Healthcare
About
Based in Ulm, Germany, and founded in 2015, NVision Quantum Technologies GmbH operates as a developer of quantum technology designed to enhance medical imaging and detect the effects of cancer therapy at the tissue level. The company was co-founded by Ilai Schwartz (CTO), Martin Plenio, and Alex Retzker. As of 2023, the company is led by its CEO, Sella Brosh, MD. In May 2026, NVision Quantum Technologies GmbH raised USD 38 million in series B funding from Abbott Capital Management, Matterwave Ventures Management, b2venture, CDP Venture Capital, Entree Capital, and Playground Ventures.
The round was part of a larger USD 55 million series B and venture debt funding. The company offers polarizers utilizing a method called parahydrogen-induced polarization (PHIP), leveraging advancements in quantum physics, chemistry, and engineering to transform metabolic MRIs that allow for early diagnosis and quicker assessment of treatment effectiveness. By employing hyperpolarization technology, the company enables the evaluation of human and animal metabolism through standard MRI, thereby facilitating applications in both preclinical and clinical settings. These include cancer diagnosis methods and the monitoring of therapy response.
The company plans to use the May 2026 funding to expand its platform from quantum sensing into quantum computing to support drug design and therapy validation.
Current Investors
b2venture, Leonard Lauder, Entree Capital
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Healthcare IT
Website
www.nvision-quantum.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
NVision Quantum Technologies GmbH - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (1,801,616.6) | 69,979.5 | - | - | - |
| % Net Margin | - | - | - | - | - |
NVision Quantum Technologies GmbH - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.